Sunday |
2:00 pm - 9:00 pm | Arrival and Check-in |
6:00 pm | Dinner |
7:30 pm - 7:40 pm | Welcome / Introductory Comments by GRC Site Staff |
7:40 pm - 9:30 pm | Keynote Session: Translating Neuroscience into Therapeutics |
| Many recent findings have shed light on the mechanisms of disease in fragile X and other autism spectrum disorders, yet therapeutic advances have proven elusive. This session will explore the challenges ahead and possible routes to enhanced clinical outcomes. |
| Discussion Leader: Laura Mamounas (National Institute of Neurological Disorders and Stroke, NIH, USA) |
7:40 pm - 8:05 pm | Kimberly Huber (University of Texas Southwestern Medical Center, USA) "Mechanisms
of Sensory Circuit Hyperexcitability in Fragile X Syndrome: Implications for Therapeutics and Biomarker Development" |
8:05 pm - 8:15 pm | Discussion |
8:15 pm - 8:40 pm | Mark Bear (Massachusetts Institute of Technology, USA) "Novel Targets for Treatment of Dysregulated Protein Synthesis in Fragile X" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Ricardo Dolmetsch (Novartis Institutes for BioMedical Research, USA) "Developing New Therapies for Neurodevelopmental Diseases" |
9:20 pm - 9:30 pm | Discussion |
Monday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | The Molecular Genetics
of ASDs and Targets of FMRP |
| FMRP regulates the translation of many other proteins, and there appears to be great overlap between the RNA binding targets of FMRP and candidate genes for autism. Here we examine the latest findings on this overlap. |
| Discussion Leader: Joel Richter (University of Massachusetts Medical School, USA) |
9:00 am - 9:35 am | Kirsty Sawicka (Rockefeller University, USA) "Translational Regulation by FMRP: Targets and Mechanism" |
9:35 am - 9:45 am | Discussion |
9:45 am - 10:20 am | David Nelson (Baylor College of Medicine, USA) "FMR1 Functions: Comparisons to Other Genetic Forms of ID/ASD" |
10:20 am - 10:30 am | Discussion |
10:30 am - 11:00 am | Coffee Break |
11:00 am - 11:35 am | Suzanne Zukin (Albert Einstein College of Medicine, USA) "Dysregulation of AMPA Receptor mRNA Targeting to Dendrites and Transcription in Fragile X" |
11:35 am - 11:45 am | Discussion |
11:45 am - 12:20 pm | Joseph Buxbaum (Icahn School of Medicine at Mount Sinai, USA) "From Gene Discovery to Novel Therapeutics in Phelan McDermid Syndrome" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Postsynaptic
Phenotypes: Signaling Pathways and Translation |
| Abnormalities in the regulation of activity-dependent translation were first identified in fragile X, but have since been recognized in many genetically determined forms of autism. This well-validated phenotype may represent a final common pathway linking many neurodevelopmental disorders. |
| Discussion Leader: Eric Klann (New York University, USA) |
7:30 pm - 8:00 pm | Joel Richter (University of Massachusetts Medical School, USA) "Ribosome Profiling and Fragile X" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:40 pm | Nahum Sonenberg (McGill University, Canada) "Impact of Metformin on FXS Mice" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Emily Osterweil (University of Edinburgh, United Kingdom) "Rebalancing Proteostasis in Fragile X" |
9:20 pm - 9:30 pm | Discussion |
Tuesday |
7:30 am - 8:30 am | Breakfast |
8:30 am | Group Photo |
9:00 am - 12:30 pm | Other Disease
Mechanisms: Presynaptic Phenotypes and Channelopathies |
| Recent findings suggest that FMRP does more than regulate dendritic protein synthesis. It also regulates presynaptic excitability via direct protein-protein interactions. In many cases, sporadic mutations in these same pathways have been found to cause ASDs. |
| Discussion Leader: David Nelson (Baylor College of Medicine, USA) |
9:00 am - 9:30 am | Vitaly Klyachko (Washington University in St. Louis, USA) "Channelopathy and Abnormal Excitability in Fragile X Syndrome: A New Role for
mGluR5" |
9:30 am - 9:40 am | Discussion |
9:40 am - 10:10 am | Leonard Kaczmarek (Yale University, USA) "Slack Channels and Protein Translation" |
10:10 am - 10:20 am | Discussion |
10:20 am - 10:45 am | Coffee Break |
10:45 am - 11:10 am | Carlos Portera-Cailliau (David Geffen School of Medicine at UCLA, USA) "Network Defects Underlying Abnormal Sensory Perception in Fmr1 Knockout Mice" |
11:10 am - 11:20 am | Discussion |
11:20 am - 11:45 am | Herve Moine (Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), France) "Is Fragile X Syndrome a Lipidopathy?" |
11:45 am - 11:55 am | Discussion |
11:55 am - 12:20 pm | Claudia Bagni (University of Rome Tor Vergata, Italy / University of Lausanne, Switzerland) "From Molecules to Behavior: Disentangling FXS and ASD" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Other Disease Mechanisms: Glial and Extracellular Phenotypes |
| FMRP also appears to regulate extracellular and retrograde signaling, and fragile X results in glial abnormalities which contribute to the overall clinical phenotype. These are additional areas of overlap with ASDs, and potential areas for therapeutic development. |
| Discussion Leader: Peter Todd (University of Michigan, USA) |
7:30 pm - 8:00 pm | Iryna Ethell (University of California, Riverside, USA) "The Role of MMP9 in Pathophysiology of FXS" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:40 pm | Laurie Doering (McMaster University, Canada) "Astrocyte Modulation in Fragile X" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Yongjie Yang (Tufts University, USA) "Astroglial Glutamate Transporter Dysfunction in Fragile X" |
9:20 pm - 9:30 pm | Discussion |
Wednesday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Circuits and
Development |
| Abnormalities in neural circuits and their development over the lifespan add new dimensions to the complexity of fragile X and genetically-determined ASDs. |
| Discussion Leader: Kimberly Huber (University of Texas Southwestern Medical Center, USA) |
9:00 am - 9:25 am | Sean McBride (Rowan University School of Osteopathic Medicine, USA) "The Convergence of Circuitry and Genetic Dissection Uncovers Insulin Dysregulation in FXS" |
9:25 am - 9:35 am | Discussion |
9:35 am - 10:00 am | Anis Contractor (Northwestern University, USA) "Disrupted GABA Signaling During Cortical Development in Fragile X Syndrome" |
10:00 am - 10:10 am | Discussion |
10:10 am - 10:35 am | Coffee Break |
10:35 am - 11:00 am | Bryan Luikart (Geisel School of Medicine at Dartmouth, USA) "Exploring the Neurophysiological Basis of Autism Using Genetic Pten Models" |
11:00 am - 11:10 am | Discussion |
11:10 am - 11:40 am | Peter Kind (University of Edinburgh, United Kingdom) "Rat Models of Fragile X and ASDs" |
11:40 am - 11:50 am | Discussion |
11:50 am - 12:20 pm | Daniel Alkon (Neurotrope BioScience, USA) "Modulation of PKC Epsilon as a Therapeutic Strategy" |
12:20 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:00 pm - 7:30 pm | Business Meeting |
| Nominations for the Next Vice Chair; Fill in Conference Evaluation Forms; Discuss Future Site and Scheduling Preferences; Election of the Next Vice Chair |
7:30 pm - 9:30 pm | Clinical Trials |
| Presentation of recent clinical trial results in subjects with
fragile X and ASDs will be featured, along with discussion of trial methodology
and lessons learned from previous efforts. |
| Discussion Leader: Laura Mamounas (National Institute of Neurological Disorders and Stroke, NIH, USA) |
7:30 pm - 8:00 pm | Mustafa Sahin (Boston Children's Hospital, USA) "Preclinical and Clinical Trials in Tuberous Sclerosis" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:40 pm | Elizabeth Berry-Kravis (Rush University Medical Center, USA) "Clinical Trials in Fragile X" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Alexander Kolevzon (Icahn School of Medicine at Mount Sinai, USA) "Developing Novel Therapeutics in Neurodevelopmental Disorders: Challenges for Clinical Trial Readiness" |
9:20 pm - 9:30 pm | Discussion |
Thursday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 12:30 pm | Clinical Trials, Imaging, and Clinical
Assessments |
| Quantification of human phenotypes by a variety of methods will be
examined in this session, as well as additional results of clinical trials. |
| Discussion Leader: Elizabeth Berry-Kravis (Rush University Medical Center, USA) |
9:00 am - 9:30 am | Frank Kooy (University of Antwerp, Belgium) "A Double Blind Crossover Trial of Ganaxolone in Patients with Fragile X Syndrome" |
9:30 am - 9:40 am | Discussion |
9:40 am - 10:10 am | Aditi Bhattacharya (Center for Brain Development and Repair, inStem, NCBS, India) "Blood-Based Biomarkers for FXS: A Journey from Mouse Brain to Human Blood" |
10:10 am - 10:20 am | Discussion |
10:20 am - 10:45 am | Coffee Break |
10:45 am - 11:15 am | John Sweeney (University of Texas Southwestern Medical Center, USA) "Translational Neurophysiological Biomarkers in FXS" |
11:15 am - 11:25 am | Discussion |
11:25 am - 11:55 am | Joseph Piven (University of North Carolina at Chapel Hill, USA) "Infant Brain and Behavior Development in Autism and Fragile X" |
11:55 am - 12:05 pm | Discussion |
12:05 pm - 12:25 pm | Gordon Wang (Stanford University, USA) "The Interplay of Synapse Diversity, Fragile X Syndrome and Drug Treatment" |
12:25 pm - 12:30 pm | Discussion |
12:30 pm | Lunch |
1:30 pm - 4:00 pm | Free Time |
4:00 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Future Directions: Emerging Therapeutic Technologies |
| New techniques for gene editing and reactivation offer promise for a wide array of genetic diseases. At the same time, new proteomic discoveries offer the potential for blood-based biomarkers and enhanced clinical testing in ASDs. |
| Discussion Leader: Peter Kind (University of Edinburgh, United Kingdom) |
7:30 pm - 8:00 pm | Gary Bassell (Emory University School of Medicine, USA) "Cellular FXS Phenotypes in hiPSC Derived Neurons" |
8:00 pm - 8:10 pm | Discussion |
8:10 pm - 8:40 pm | Eric Klann (New York University, USA) "Resetting Translational Homeostasis in FXS" |
8:40 pm - 8:50 pm | Discussion |
8:50 pm - 9:20 pm | Xinyu Zhao (University of Wisconsin-Madison, USA) "New Strategies for Treating Fragile X: Getting to the Root of the Problem" |
9:20 pm - 9:30 pm | Discussion |
Friday |
7:30 am - 8:30 am | Breakfast |
9:00 am | Departure |